BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Zydelig® (idelalisib): Restrictions of use

2016.03.24

Active substance: idelalisib

The company Gilead Sciences GmbH is circulating information on interim recommendations on restrictions of use of Zydelig.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 319KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK